| 1 | Adequate Sleep (7β9 hrs) | π S | π§ Lifestyle | Strongest lifestyle predictor of life expectancy β surpasses diet, exercise, and social ties. Sleep insufficiency ranked 2nd only to smoking in predicting shorter lifespan across 3,000+ U.S. counties. Sleep regularity (20β48% lower mortality) is even more predictive than duration alone. Affects cardiovascular, immune, metabolic, and cognitive systems. | Sleep debt cannot be fully recovered on weekends. Irregular schedules disrupt circadian rhythms independently. Oversleeping (>10 hrs) also associated with worse outcomes (though likely a marker of illness rather than cause). | 7β9 hrs nightly; consistent schedule; dark, cool room. McAuliffe et al., SLEEP Advances, Dec 2025; Windred et al., SLEEP 47(1), 2024 (60,977 UK Biobank); 2025 meta-analysis (PMC12181477, 5 low-bias cohorts): least-regular sleepers had 20β88% higher all-cause mortality independent of duration; Scientific Reports 15, 2025 confirms. |
| 2 | Regular Exercise (varied types) | π S | π Exercise | 20β31% lower all-cause mortality at recommended levels; 2β4Γ the minimum shows further reduction without harm. Exercise variety adds 19% additional mortality reduction independent of total volume (Harvard/BMJ 2026, 111,467 participants). | Overtraining without recovery can suppress immune function. High-volume endurance without strength training β muscle/bone loss (see Debunked section). Injury risk with poor form. | 150+ min/wk moderate or 75 min vigorous; mix cardio, strength, balance. Han, Hu et al., BMJ Medicine, Jan 2026 (PMID 41574252, NHS+HPFS, nβ111,000, 30-yr follow-up); Lee et al., Circulation 146(7), 2022. |
| 3 | Mediterranean / Anti-Inflammatory Diet | π S | π₯ Nutrition | ~30% reduction in major cardiovascular events (PREDIMED, 7,447 participants). 9% lower overall mortality per 2-point adherence increase. Reduced cognitive decline, lower AMD risk, hearing protection, improved gut microbiome. Nature Medicine 2025: confirmed as the most validated dietary pattern for healthy aging. | No single "perfect" diet; adherence is key. Quality olive oil and fish are expensive. Not inherently low-calorie (can still overeat). Cultural/taste barriers. | Olive oil, fish, vegetables, legumes, nuts, whole grains; limit processed food. Estruch et al., NEJM 378(25), 2018; Tessier et al., Nature Medicine 31, March 2025 (PMID 40128348, n=105,015, 30 yrs); 2024 MA in Nutrients 16(22):3947 (PMID 39599734, 28 studies, n=679,259): high adherence β 23% lower all-cause and 27% lower CV mortality. |
| 4 | Not Smoking / Avoiding Toxins | π S | π§ Lifestyle | Smoking cuts β₯10 years from life expectancy. Quitting before 40 reduces excess mortality ~90%. Most consistent accelerator of epigenetic aging across every tissue. Also the #1 modifiable risk factor for AMD, skin aging, hearing loss, and hair loss. | Nicotine withdrawal is difficult. Vaping is less harmful than cigarettes but still delivers nicotine + formaldehyde + acrolein β NOT safe. Secondhand smoke exposure is also significant. | Never smoke. Jha et al., NEJM 368(4), 2013; U.S. Surgeon General Report, 2014. |
| 5 | Social Connection & Purpose | π΅ A | π§ Lifestyle | 50% increased likelihood of survival with stronger social ties (comparable to quitting smoking). Positive aging self-perception = 7.5 extra years. Loneliness accelerates biological aging and immune suppression. | Hard to "supplement" β requires genuine engagement. Toxic relationships may be worse than isolation. Digital connection is not equivalent to in-person. | Maintain friendships; group activities; cultivate purpose. Holt-Lunstad et al., PLoS Medicine 7(7), 2010 (148 studies, 308,849 people); Levy et al., JPSP 83(2), 2002. |
| 6 | Strength / Resistance Training | π΅ A | π Exercise | 10β17% lower all-cause mortality; preserves muscle mass, bone density; reduces falls, metabolic disease, and sarcopenia (a major mortality predictor). Maximum benefit at 30β60 min/week. | Injury risk with excessive load or poor technique. Requires progressive overload for continued adaptation. Often neglected in favor of cardio. | 2β3x/week compound lifts; progressive overload; prioritize after 40. Momma et al., BJSM 56(13), 2022 (meta-analysis). |
| 7 | Cardiorespiratory Fitness (VO2 Max) | π΅ A | π Exercise | Elite fitness vs. lowest quintile: 5Γ mortality reduction. Each 1-MET increase = 13β15% lower mortality. No harmful upper limit found. VO2 max now recognized as the single best functional age biomarker β correlates with glucose control, visceral fat, sleep, and mood. | Genetic ceiling exists. Requires consistent training. Testing requires maximal effort (graded exercise test). Improvement slows with higher fitness levels. | HIIT 1β2x/week; Zone 2 training 2β3x/week; measure VO2 max. Mandsager et al., JAMA Netw Open 1(6), 2018 (122,007 patients); 2024 BMI-stratified MA (PMID 39537313): unfit individuals at any BMI have 2β3Γ higher CV/all-cause mortality vs. fit β fitness dominates BMI. 2025 MA (J Gerontol A 2025): aerobic fitness associated with telomere preservation. |
| 8 | Vitamin D3 Supplementation | π΅ A | π Supplement | VITAL trial sub-study: 2,000 IU/day reduced telomere attrition by 140 bp over 4 years β equivalent to ~3 years of slowed biological aging. Also reduced advanced cancer by 17% and autoimmune disease by 22%. 40β50% of population is deficient. | Toxicity at >10,000 IU/day long-term (hypercalcemia). Kidney stone risk. No benefit if already replete (>40 ng/mL). The D-Health trial (monthly high-dose) showed no telomere benefit β daily moderate dosing is key. | 2,000β5,000 IU/day; test 25(OH)D annually; target >40 ng/mL. Zhu et al., AJCN, May 2025 (VITAL/1,054 participants); DO-HEALTH (Bischoff-Ferrari et al., Nature Aging, Feb 2025, PMID 39900648, n=777 adults >70): 2,000 IU/day + omega-3 + strength training slowed PhenoAge, GrimAge2, and DunedinPACE by 2.9β3.8 months over 3 years β effects additive. |
| 9 | Omega-3 Fatty Acids (EPA/DHA) | π΅ A | π Supplement | Highest vs. lowest omega-3 index: 4.7-year life expectancy increase (Framingham Offspring). 17 prospective studies (42,466 people): 13% lower all-cause mortality. Anti-inflammatory via resolvins/protectins. Benefits span cardiovascular, brain, eyes, joints, skin, and hearing. | Fishy burps. Blood thinning >3g/day. May increase LDL in some. Quality varies β use IFOS-tested. Rancid fish oil is harmful. VITAL (Zhu et al., AJCN 2025, PMID 40409468): 1g/day marine Ο-3 did NOT affect leukocyte telomere length over 4 yrs. DO-HEALTH (Bischoff-Ferrari et al., Nature Aging 2025, n=777): 1g/day slowed PhenoAge, GrimAge2, and DunedinPACE ~3 months over 3 yrs. Divergence likely reflects endpoint (telomere length vs. methylation clocks). | 1β2g EPA+DHA daily; fatty fish 2x/week; target omega-3 index β₯8%. McBurney et al., AJCN 114(4), 2021; Harris et al., Nature Communications 12, 2021. |
| 10 | Stress Reduction / Meditation | π΅ A | π§ Lifestyle | 20 RCTs: meditation reduced NF-ΞΊB, CRP, and inflammation markers. Increased telomerase activity. Altered expression of inflammation and aging genes with effects persisting at 1-month follow-up. Highest-stress individuals had telomeres ~10 years older than low-stress. | Benefits require consistent practice (not occasional). Not a substitute for addressing root causes of stress. Some individuals experience increased anxiety during meditation (rare). | Daily meditation; creative hobbies; nature exposure. Black & Slavich, Ann NY Acad Sci 1373(1), 2016; Epel et al., PNAS 101(49), 2004. |
| 11 | GLP-1 Receptor Agonists | π£ B | π Pharma | SELECT trial (17,604 participants): semaglutide 2.4mg reduced major cardiovascular events by 20% in overweight/obese adults without diabetes. Meta-analysis of 8 trials (60,080): 12% lower all-cause mortality, 14% lower MACE. Reduces inflammation, improves metabolic flexibility, endothelial function. Cognitive outcomes mixed: oral semaglutide failed phase-3 in early Alzheimer's (EVOKE / EVOKE+, n=3,808, Nov 2025); liraglutide showed slowed atrophy and ~18% slower cognitive decline in phase 2b (Femminella et al., Nature Medicine, Dec 2025). SELECT-LIFE (AHA 2025): CV benefit converges with placebo ~16 months after discontinuation. | Prescription only. GI side effects (nausea, vomiting) common. Lean mass loss = 25β40% of total weight lost on semaglutide/tirzepatide (2026 Am J Med review) β preserve with resistance training + 1.6 g/kg protein. Pancreatitis risk. Very expensive. Rebound weight + CV-benefit loss on discontinuation. Thyroid C-cell tumor concern in rodents (not confirmed in humans). | Prescription only; discuss with doctor if overweight. Lincoff et al., NEJM 389(24), 2023 (SELECT); Sattar et al., Lancet Diabetes Endocrinol 9(10), 2021; Femminella et al., Nature Medicine, Dec 2025; EVOKE/EVOKE+ topline Nov 2025. |
| 12 | Time-Restricted Eating / Fasting | π£ B | π₯ Nutrition | Reduces risk factors for heart disease, cancer, metabolic disease. Three cycles of 5-day fasting-mimicking diet reduced body weight, BP, fasting glucose, IGF-1, triglycerides, cholesterol, and CRP in 100 healthy participants. TRF improves insulin sensitivity and circadian alignment. | Not suitable for everyone (eating disorders, underweight, pregnancy). Excessive restriction may impair muscle gain. Adherence is challenging. Observational AHA 2024 abstract (n>20,000) linked <8 hr eating windows to 91% higher CV mortality at 8-yr follow-up; signal not yet peer-reviewed and 2025 Frontiers in Nutrition perspective (doi 10.3389/fnut.2025.1524125) urges caution pending publication. 2025 RCT MA (Front Nutr, doi 10.3389/fnut.2025.1631477): TRE without caloric restriction yields modest BP/lipid improvements, no mortality data. Treat narrow windows cautiously long-term. | Eat within 8β12 hr window; periodic fasting-mimicking cycles. Longo & Panda, Cell Metabolism 23(6), 2016; Wei et al., Sci Transl Med 9(377), 2017. |
| 13 | Metformin | π£ B | π Pharma | Activates AMPK, inhibits mTOR, reduces inflammation, improves mitochondrial function. Observational: UK data (180,000 patients) showed metformin-treated diabetics had 15% lower all-cause mortality than matched non-diabetic controls. TAME trial (first FDA-approved aging trial) results pending. | Prescription only. GI side effects (diarrhea, nausea). B12 depletion with long-term use. May blunt some exercise adaptations (mixed evidence). Lactic acidosis risk (rare, mainly in renal impairment). | Prescription only; TAME trial pending. Barzilai et al., Cell Metabolism 23(6), 2016. |
| 14 | NAD+ Precursors (NMN / NR) | π£ B | π Supplement | Raises NAD+ ~50β60% in blood. NMN improved muscle insulin sensitivity ~25% in prediabetic women (Yoshino 2021). NR reduced systolic BP and aortic stiffness (Martens 2018). NAD+ supports DNA repair, sirtuin activation, mitochondrial function. | β οΈ Cancer caveat: 2026 Cancer Letters found NMN/NR helped pancreatic cancer cells survive chemo. 64% of NMN products contain <1% labeled amount. Expensive. Long-term safety unknown. Not recommended during active cancer treatment. | NMN 250β500mg or NR 300mg daily; third-party tested only. Yoshino et al., Science 372(6547), 2021; Martens et al., Nature Communications 9, 2018. |
| 15 | CoQ10 (Ubiquinol) | π£ B | π Supplement | Essential for mitochondrial ATP production. Levels decline ~40% with age and statin use. Q-SYMBIO trial (420 patients, 10 countries): 42% reduction in all-cause mortality, 43% in cardiovascular mortality in heart failure patients. | Expensive (ubiquinol > ubiquinone). GI upset. May lower blood pressure. Interacts with warfarin. Take with fat. | 100β200mg/day ubiquinol; take with fat. Mortensen et al., JACC: Heart Failure 2(6), 2014. |
| 16 | Rapamycin (low-dose) | π£ B | π Pharma | Most reliable lifespan extender in mammalian models (NIA ITP: 9β14% lifespan extension even started late in life). PEARL trial (2025): first human RCT β 48-week, double-blind, placebo-controlled. Safe at 5β10mg/week. Women on 10mg showed significant improvements in lean tissue mass and pain; men showed bone mineral improvement. Rapamycin + acarbose: up to 36.6% lifespan increase in mice. | Prescription only. Immune suppression at high doses (transplant doses are 10β50Γ higher). Mouth sores, lipid elevations. PEARL trial was small and relied partly on self-reporting. Long-term human safety for anti-aging use is unknown. Much larger trials needed. | Prescription only; human trials ongoing. Moel et al., Aging 17, 908β936, 2025 (PEARL); Harrison et al., Nature 460, 2009 (NIA ITP). |
| 17 | Quercetin (senolytic) | βͺ C | π Supplement | Flavonoid with senolytic properties β clears damaged senescent cells when combined with dasatinib (D+Q). D+Q extended healthspan and lifespan ~36% in aged mice. Human pilot: feasible and reduced senescent cell burden in pulmonary fibrosis. Also anti-inflammatory, antihistamine. | GI upset. Poor bioavailability (take with fat). Senolytic effect requires intermittent dosing with dasatinib (prescription). Continuous quercetin alone is NOT senolytic. | 500β1,000mg/day (or intermittent with dasatinib under medical supervision). Zhu et al., Aging Cell 14(4), 2015; Justice et al., EBioMedicine, 2019; STAMINA pilot (Gonzales et al., eBioMedicine, 2025, doi 10.1016/j.ebiom.2025.105578): D+Q in older adults with MCI safe and feasible but cognitive gains non-significant; no meaningful tau/amyloid change. Phase 2 trials ongoing. |
| 18 | Urolithin A | βͺ C | π Supplement | Activates mitophagy (clearing damaged mitochondria). Only ~40% produce it naturally from gut metabolism of ellagic acid. JAMA Network Open 2022 RCT (Liu et al., n=66 older adults, 4 mo at 1,000mg): primary ATP-production endpoint was null; secondary muscle endurance and mitochondrial biomarkers improved. First human trial (2019): improved mitochondrial biomarkers after 4 weeks. 2024 RCT in resistance-trained males (Bashir et al., JISSN 2024) and 2025 soccer-academy pilot show mixed strength/aerobic signals. | Expensive. Limited long-term data. GI discomfort. Mitopure (Timeline) is the studied branded form. Young, well-trained individuals likely see less benefit (exercise already activates mitophagy). | 500β1,000mg/day. Andreux et al., Nature Metabolism 1, 2019; Liu et al., JAMA Netw Open 5(1):e2144279, 2022 (PMID 35050355); Bashir et al., JISSN, 2024. |
| 19 | Taurine | βͺ C | π Supplement | 2023 Science paper (Singh et al.): taurine supplementation increased lifespan 10β12% in mice, improved healthspan in monkeys. Reduces cellular senescence in animal models. Found in meat, fish, dairy. Very safe (up to 6g/day studied). | 2025 counterevidence is strong: Marcangeli et al., Aging Cell 24(11):e70191, 2025 (n=137 men 20β93): no association of circulating taurine with age, muscle mass, strength, performance, or mitochondrial function. Fernandez/de Cabo et al., Science, June 2025 (PMID 40472098, doi 10.1126/science.adl2116): across humans, monkeys, and mice, taurine levels typically rose or stayed constant with age β unlikely a reliable aging biomarker. Human longevity translation not supported by adequately powered RCT. | 1β3g/day. Inexpensive and very safe. Singh et al., Science 380(6649), 2023; Marcangeli et al., Aging Cell 24(11):e70191, 2025; Fernandez & de Cabo et al., Science, June 2025. |
| 20 | Spermidine | βͺ C | π Supplement | Promotes autophagy; linked to lower mortality in observational data. Bruneck Study: highest vs. lowest dietary tertile = HR 0.56 for all-cause mortality over 20 years. Improved cardiac function in mice. | Human evidence mostly observational. RCTs are small. Dose standardization difficult. | 1β5mg/day; or eat aged cheese, mushrooms, soy, wheat germ. Eisenberg et al., Nature Medicine 22, 2016; 2025 Ageing Research Reviews-class synthesis (PMC12519323): cognition RCTs mixed/underpowered (SmartAge null at 12 mo); observational mortality/CV signal holds. POLYCAD RCT (Denmark, Trials 2025) ongoing. |
| 21 | Probiotics / Gerobiotics | βͺ C | π Supplement | Emerging "gerobiotics" concept: specific probiotic strains that attenuate aging mechanisms. Akkermansia muciniphila improved intestinal senescence and extended healthspan in aged mice. Specific strains support gut barrier integrity, immune function, and nutrient absorption. ISSN position stand supports probiotics for athletes. | Not all strains are equal. Effects are strain-specific. May worsen SIBO. Quality/viability varies. Most evidence is animal-based for longevity claims. | Strain-specific: L. rhamnosus GG (immune); B. lactis (gut barrier); Akkermansia (emerging). Duan et al., 2022 (Akkermansia); JΓ€ger et al., JISSN 16, 2019; 2025 Akk11 synbiotic RCT (Annals of Microbiology, doi 10.1186/s13213-025-01839-1, n=110 overweight adults): metabolic/inflammatory benefits; Front Immunol 2025;16:1733575 mechanistic review on A. muciniphila in aging. |
| 22 | Resveratrol | βͺ C | π Supplement | Polyphenol from grape skin; activates SIRT1 in theory. Some evidence for improved blood flow, reduced inflammation. | Poor oral bioavailability (<1%). May impair exercise adaptations at high doses. Estrogenic at high doses. Human evidence weak and inconsistent. | Evidence is weak; pterostilbene may be superior. Bitterman & Chung, Cell Mol Life Sci 72(8), 2015. |
| 23 | Epigenetic Reprogramming | βͺ C | 𧬠Experimental | Reversed aging and restored vision in mice via partial Yamanaka factors (OSK). Whole-body partial reprogramming rejuvenated multiple tissues. | Not available for humans. Risk of teratoma formation. First human trials expected 2026β2027. | Experimental only. Lu et al., Nature 588, 2020; Browder et al., Nature Aging, 2022. |
| 24 | Young Fecal Microbiota Transplant | βͺ C | 𧬠Experimental | FMT from young to aged mice reversed aging hallmarks in gut, brain, and eye. Agedβyoung FMT accelerated aging phenotypes. | Not widely available. Infection risk. Regulatory barriers. Variable donor quality. | Support gut health via fiber and fermented foods. Parker et al., Microbiome 10, 68, 2022. |
| 25 | CPAP / PAP for Moderate-to-Severe OSA | π΅ A | π Pharma | 37% lower all-cause mortality (HR 0.63, 95% CI 0.56β0.72) and 55% lower CV mortality (HR 0.45, 0.29β0.72) with PAP therapy. Effect is dose-responsive on adherence β β₯4 hr/night needed for full CV benefit. OSA is grossly under-diagnosed; loud snoring + daytime sleepiness + witnessed apneas warrant a sleep study. | Adherence is the main barrier. Mask discomfort. Not indicated for mild OSA without symptoms. Requires diagnosis via sleep study. | Pengo et al., Lancet Respiratory Medicine, 2025 (doi 10.1016/S2213-2600(25)00002-5, MA of RCTs + confounder-adjusted non-randomized); JAMA Network Open, 2025 (older adults cohort). |
| 26 | Vitamin K2 (MK-7) | βͺ C | π Supplement | Activates Matrix GLA Protein (prevents arterial calcification) and osteocalcin (Caβbones). 2025 SR: K2 raised carboxylated osteocalcin and bone ALP, reduced dp-ucMGP in 7 of 7 RCTs; slowed coronary artery calcification in 4 of 14. Bone is the more robust outcome. | Interacts with warfarin. Generally safe. MK-7 > MK-4 (longer half-life). | 100β200 mcg MK-7/day. Front Endocrinol 16:1703116, 2025; J Bone Miner Metab-class MA, 2024 (PMC11631259): lumbar BMD improvement, fracture-risk reduction RR 0.43 in postmenopausal subgroup. |